6533b85cfe1ef96bd12bc0d2
RESEARCH PRODUCT
A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Giovanni MergoniMarco MeletiMaddalena ManfrediMatteo GoldoniStefania SalvagniPaolo VescoviElisabetta Merigosubject
Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugdescription
Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occurrence of ONJ. Conclusions This study demonstrated the importance of beginning dental prevention before zoledronic acid exposure in reducing ONJ occurrence, especially in the long term. The results of this research show that control of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are recommended in order to reduce the risk of ONJ development. Key words:Osteonecrosis of the jaw, dental prevention, zoledronic acid, incidence.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-04-01 | Medicina oral, patologia oral y cirugia bucal |